FY2025 · ended Dec 31, 2025 · Revenue $1.38M, -0.3% YoY · Filed Apr 15, 2026
Northwest Biotherapeutics Inc (NWBO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.4 million and a net loss of $60.2 million. Free cash flow was -$46.3 million. As of Jun 30, 2026 it held $595,000 in cash and investments and $56.4 million in total debt.
Revenue (TTM)
$2.17M
+98.6% vs year-ago TTM
Net income (TTM)
$-37.73M
+54.2% vs year-ago TTM
Operating cash flow (TTM)
$-48.34M
-8.6% vs year-ago TTM
Free cash flow (TTM)
$-49.77M
EPS (TTM)
$-0.02
+42.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.61B
+15.5% vs prior year
Net cash
$-55.85M
as of Jun 30, 2026
Operating margin
-2316.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NWBO (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1072379
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.9M | $1.7M | $1.0M |
| Operating income | -$59.9M | -$66.5M | -$55.5M | -$67.2M | -$52.7M |
| Net income | -$60.2M | -$83.8M | -$62.6M | -$105.0M | $179.1M |
| Diluted EPS | -$0.04 | -$0.07 | -$0.06 | -$0.10 | -$0.06 |
| Operating cash flow | -$44.8M | -$57.0M | -$53.6M | -$52.8M | -$38.3M |
| Free cash flow | -$46.3M | — | — | — | — |
| Total assets | $81.3M | $26.7M | $27.9M | $31.3M | $40.2M |
| Total liabilities | $128.9M | $105.7M | $74.9M | $136.4M | $164.2M |
| Stockholders' equity | -$60.3M | -$94.5M | -$65.8M | -$128.1M | -$124.0M |
| Cash and investments | $3.0M | $2.2M | $2.1M | $7.0M | $15.2M |
| Total debt | $64.8M | $67.4M | $45.6M | $26.3M | $37.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt
|
Oct 30, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 20, 2026 | Jul 17, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
All 803 Northwest Biotherapeutics Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.